再生元制药

最新新闻

• 评级变动
  Baird Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $761
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $900
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Argus Research Upgrades Regeneron Pharmaceuticals(REGN.US) to Buy Rating, Announces Target Price $850
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Robert W. Baird Sticks to Their Hold Rating for Regeneron (REGN)
  TipRanks · 2026/10/2
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/9/10
• 评级变动
  Leerink Partners Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Announces Target Price $824
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $930
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Leerink Partners Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 公司公告
  LYC Healthcare: MEXTER TECHNOLOGY BERHAD (MEXTER) • PROPOSED ACQUISITION BY ITS 80% OWNED SUBSIDIARY MEXCOMM SDN BHD (777810-D) OF A 49% EQUITY INTEREST IN E-G6 SOLUTION (THAILAND) CO. LTD. (REGN NO. 0105551096920) (“THE COMPANY”) (“ACQUISITION”
  Bursa Malaysia · 2012/8/6
• J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $950
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,030
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $920
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Raises Target Price to $779
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  HSBC Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $920
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $972
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Raises Target Price to $810
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $917
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $780
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $750 to $960
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $900
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $965
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,000
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
  \u5e02\u573a\u8d44\u8baf · 2026/7/9

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。